JP6329135B2 - カバジタキセルの結晶形態を有する結晶、その調製方法およびその使用 - Google Patents

カバジタキセルの結晶形態を有する結晶、その調製方法およびその使用 Download PDF

Info

Publication number
JP6329135B2
JP6329135B2 JP2015514346A JP2015514346A JP6329135B2 JP 6329135 B2 JP6329135 B2 JP 6329135B2 JP 2015514346 A JP2015514346 A JP 2015514346A JP 2015514346 A JP2015514346 A JP 2015514346A JP 6329135 B2 JP6329135 B2 JP 6329135B2
Authority
JP
Japan
Prior art keywords
cabazitaxel
crystalline form
mixture
crystal
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518012A (ja
Inventor
リー，ジン
ヤオ，チュエンシン
Original Assignee
チョンチン・タイハオ・ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョンチン・タイハオ・ファーマシューティカル・カンパニー・リミテッド filed Critical チョンチン・タイハオ・ファーマシューティカル・カンパニー・リミテッド
Publication of JP2015518012A publication Critical patent/JP2015518012A/ja
Application granted granted Critical
Publication of JP6329135B2 publication Critical patent/JP6329135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
JP2015514346A 2012-07-25 2013-07-18 カバジタキセルの結晶形態を有する結晶、その調製方法およびその使用 Active JP6329135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210259595.3 2012-07-25
CN201210259595.3A CN102746258B (zh) 2012-07-25 2012-07-25 卡巴他赛的结晶形式及其制备方法
PCT/CN2013/079575 WO2014015760A1 (zh) 2012-07-25 2013-07-18 卡巴他赛的结晶形式及其制备方法

Publications (2)

Publication Number Publication Date
JP2015518012A JP2015518012A (ja) 2015-06-25
JP6329135B2 true JP6329135B2 (ja) 2018-05-23

Family

ID=47026807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514346A Active JP6329135B2 (ja) 2012-07-25 2013-07-18 カバジタキセルの結晶形態を有する結晶、その調製方法およびその使用

Country Status (8)

Country Link
US (1) US9353076B2 (enExample)
EP (2) EP2835369B1 (enExample)
JP (1) JP6329135B2 (enExample)
CN (1) CN102746258B (enExample)
AU (2) AU2013295924B2 (enExample)
CA (2) CA2870569A1 (enExample)
IN (1) IN2014MN01962A (enExample)
WO (1) WO2014015760A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2688877B1 (en) 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN104220431A (zh) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) * 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103819428B (zh) * 2012-11-19 2016-01-13 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
KR101429543B1 (ko) 2012-12-13 2014-08-14 주식회사 삼양바이오팜 카바지탁셀의 신규 결정형 및 그 제조방법
CN103044364B (zh) * 2013-01-07 2016-01-20 重庆泰濠制药有限公司 一种卡巴他赛无定形晶及其制备方法
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
CN103450119B (zh) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 一种卡巴他赛晶型w及其制备方法
EP2865674A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN105461664A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n5型物质及制备方法和其组合物与用途
CN105461665A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n6型物质及制备方法和其组合物与用途
CA3010514A1 (en) 2016-01-15 2017-07-20 Zhuhai Beihai Biotech Co., Ltd. Compositions and formulations including cabazitaxel and human serum albumin
EP3509569A1 (en) * 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
CN112055588B (zh) 2018-04-20 2023-09-08 珠海贝海生物技术有限公司 卡巴他赛的制剂和组合物
CN113429369B (zh) * 2021-07-23 2022-12-02 无锡紫杉药业有限公司 一种高效的卡巴他赛纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
CN101525321B (zh) * 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
CN102060815B (zh) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
EP2688877B1 (en) * 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
US9772339B2 (en) * 2011-09-30 2017-09-26 Life Technologies Corporation Methods and systems for image analysis identification
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
DE112012004569T5 (de) * 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
PL2785701T3 (pl) * 2011-11-28 2019-08-30 Fresenius Kabi Oncology Limited Krystaliczna postać kabazytakselu i sposób jej otrzymywania
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
CN104220431A (zh) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN104583189A (zh) * 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法

Also Published As

Publication number Publication date
CN102746258B (zh) 2015-02-04
CA2909500A1 (en) 2014-01-30
US20150141674A1 (en) 2015-05-21
CN102746258A (zh) 2012-10-24
WO2014015760A1 (zh) 2014-01-30
EP3067348A1 (en) 2016-09-14
AU2013295924B2 (en) 2016-02-18
EP2835369A4 (en) 2015-12-02
CA2870569A1 (en) 2014-01-30
AU2013295924A1 (en) 2014-10-23
EP2835369B1 (en) 2019-04-03
JP2015518012A (ja) 2015-06-25
AU2016200343B2 (en) 2017-03-30
IN2014MN01962A (enExample) 2015-07-10
US9353076B2 (en) 2016-05-31
CA2909500C (en) 2018-01-09
EP2835369A1 (en) 2015-02-11
AU2016200343A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
JP6329135B2 (ja) カバジタキセルの結晶形態を有する結晶、その調製方法およびその使用
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のｉ型結晶およびその製造法
JP6537601B2 (ja) アザ二環式化合物の結晶
KR101917557B1 (ko) 3,5-2치환 벤젠알키닐 화합물의 결정
CN111164085B (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
SG185594A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US11639341B2 (en) Crystal form of tipifarnib and method of treatment thereof
WO2011023146A1 (en) Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
EA028351B1 (ru) Твердые формы гидрохлорида вемурафениба
ES2928706T3 (es) Formas sólidas de un compuesto farmacéuticamente activo
CN114727994B (zh) 优替德隆半水合物单晶及其制备方法与应用
WO2017025045A1 (zh) 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的新晶型及其制备方法
KR101596554B1 (ko) 펩타이드계 물질의 결정체 및 그의 제조방법과 용도
WO2012160568A1 (en) Process for preparing docetaxel trihydrate polymorph
JP2016504364A (ja) コビシスタット塩
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
EP3752500A1 (en) Solid-state forms of abemaciclib, their use and preparation
WO2017042837A2 (en) Stable crystalline form of regadenoson
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
CN112778290A (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
WO2015074281A1 (zh) 力格赛狄盐及其晶型、它们的制备方法和用途
US20170327467A1 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and use thereof (as amended)
CN103539683A (zh) 治疗硬化病的药物的新晶型及其制备方法
EA046959B1 (ru) Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его соль
WO2017035170A1 (en) Solid state forms of cediranib maleate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170227

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180419

R150 Certificate of patent or registration of utility model

Ref document number: 6329135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250